GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Kindstar Globalgene Technology Inc (HKSE:09960) » Definitions » EBIT

Kindstar Globalgene Technology (HKSE:09960) EBIT : HK$23 Mil (TTM As of Jun. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Kindstar Globalgene Technology EBIT?

Kindstar Globalgene Technology's earnings before interest and taxes (EBIT) for the six months ended in Jun. 2024 was HK$21 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Jun. 2024 was HK$23 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Kindstar Globalgene Technology's annualized ROC % for the quarter that ended in Jun. 2024 was -1.48%. Kindstar Globalgene Technology's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2024 was 5.25%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Kindstar Globalgene Technology's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2024 was -14.73%.


Kindstar Globalgene Technology EBIT Historical Data

The historical data trend for Kindstar Globalgene Technology's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kindstar Globalgene Technology EBIT Chart

Kindstar Globalgene Technology Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBIT
Get a 7-Day Free Trial -183.68 -1,138.05 -1,778.15 95.85 56.17

Kindstar Globalgene Technology Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 85.74 14.17 54.63 1.54 21.26

Competitive Comparison of Kindstar Globalgene Technology's EBIT

For the Diagnostics & Research subindustry, Kindstar Globalgene Technology's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kindstar Globalgene Technology's EV-to-EBIT Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Kindstar Globalgene Technology's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Kindstar Globalgene Technology's EV-to-EBIT falls into.



Kindstar Globalgene Technology EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$23 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Kindstar Globalgene Technology  (HKSE:09960) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Kindstar Globalgene Technology's annualized ROC % for the quarter that ended in Jun. 2024 is calculated as:

ROC % (Q: Jun. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2023 ) + Invested Capital (Q: Jun. 2024 ))/ count )
=-37.25 * ( 1 - 30.14% )/( (1400.404 + 2105.126)/ 2 )
=-26.02285/1752.765
=-1.48 %

where

Invested Capital(Q: Dec. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=4013.303 - 463.833 - ( 2215.175 - max(0, 813.521 - 2962.587+2215.175))
=1400.404

Invested Capital(Q: Jun. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=4122.384 - 436.348 - ( 1664.388 - max(0, 875.586 - 2456.496+1664.388))
=2105.126

Note: The Operating Income data used here is two times the semi-annual (Jun. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Kindstar Globalgene Technology's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Jun. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2023  Q: Jun. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=42.52/( ( (616.658 + max(130.099, 0)) + (679.585 + max(192.361, 0)) )/ 2 )
=42.52/( ( 746.757 + 871.946 )/ 2 )
=42.52/809.3515
=5.25 %

where Working Capital is:

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(686.32 + 53.268 + 23.523) - (463.833 + 0 + 169.179)
=130.099

Working Capital(Q: Jun. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(710.861 + 54.362 + 16.906) - (436.348 + 0 + 153.42)
=192.361

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Jun. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Kindstar Globalgene Technology's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Jun. 2024 )
=22.799/-154.820
=-14.73 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Kindstar Globalgene Technology EBIT Related Terms

Thank you for viewing the detailed overview of Kindstar Globalgene Technology's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Kindstar Globalgene Technology Business Description

Traded in Other Exchanges
N/A
Address
Biolake D2-1, 666 Gaoxin Road, East Lake High Tech Zone, Hubei Province, Wuhan, CHN
Kindstar Globalgene Technology Inc is principally engaged in the provision of clinical testing services in China. It organizes the business into the following segments; hematology testing, genetic disease and rare disease testing, infectious disease testing, oncology testing, neurology testing, maternity-related testing, COVID-19-related testing, routine testing, scientific research services and CRO, and other segments provide testing services for R&D projects and others and miscellaneous services.
Executives
Jackson Hole Trust Company
Huang Bo
Kernelstar Limited 2301 Trustee
Kastle Limited 2301 Trustee
Guo Gui-rong 2202 Interest of your spouse
Huang Shiang 2101 Beneficial owner
Huang Zuie-chin 2101 Beneficial owner
Tu Zanbing
Chan Tan Ching Fen 2307 Founder of a discretionary trust who can infl
Ningbo Meishan Bonded Port Zone Ruifu Bojian Investment Management Co., Ltd.
Cpechina Fund Iii, L.p. 2201 Interest of corporation controlled by you
Cpe Holdings Limited 2201 Interest of corporation controlled by you
Cpe Holdings International Limited 2201 Interest of corporation controlled by you
Cpe Funds Iii Limited 2201 Interest of corporation controlled by you
Ck Lab Tech Investment Limited 2101 Beneficial owner

Kindstar Globalgene Technology Headlines

No Headlines